A Review of the 2018 Cholesterol Guidelines: Focus on Nonstatin Lipid-lowering Drugs

The 2018 Cholesterol Clinical Practice Guidelines were released and endorsed by multiple associations including the National Lipid Association, American Diabetes Association, American Pharmacists Association, American Society for Preventive Cardiology, and Preventive Cardiovascular Nurses Association, to name a few.1 Since the prior guideline and addendums, studies have been published showing the benefit of nonstatin lipid-lowering agents. Ezetimibe demonstrated atherosclerotic cardiovascular disease (ASCVD) morbidity reduction (specifically myocardial infarction and stroke) in patients with acute coronary syndrome when added to a moderate-intensity statin,2 and both evolocumab3 and alirocumab4 have shown further reduction of ASCVD risk in secondary prevention.
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Tags: Prescription Pad Source Type: research